Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: Interim analysis of an ongoing PONCAP study

F. Boccardo, A. Decensi, D. Guarneri, A. Rubagotti, F. Oneto, G. Martorana, L. Giuliani, U. Delli Ponti, S. Petracco, P. Cortellini, M. Ziveri, V. Ferraris, G. P. Burttini, R. Epis, G. Comeri, G. Gallo, P. Marchi, A. Reggioni, A. Zanollo

Research output: Contribution to journalArticlepeer-review

Abstract

Since March 1987, 304 evaluable patients with stage C and D prostate cancer have been entered into a prospective trial comparing Zoladex and Zoladex plus flutamide. To date, there has been no significant difference in overall and progression-free survival between the 2 treatment groups. However, combined treatment produced a higher response rate (particularly in stage D patients) and a more rapid normalization of abnormal prostatic acid phosphatase levels. In addition, more prompt relief of bone pain was evident in the Zoladex plus flutamide group. However, significantly more side-effects were associated with combined treatment. These findings should be considered with caution because they form an interim analysis, and follow-up time is short. The results do suggest, however, that there is no particular advantage in using a combination of Zoladex plus flutamide compared to adding flutamide on failure of treatment with Zoladex alone.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalEuropean Urology
Volume18
Issue numberSUPPL. 3
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: Interim analysis of an ongoing PONCAP study'. Together they form a unique fingerprint.

Cite this